BRIEF-Janssen Research & Development submits supplemental application to FDA to update prescribing information for Xarelto

* Janssen Research & Development says it has submitted supplemental new drug application to u.s. Fda to update prescribing information for xarelto
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.